BeiGene

stop shut down close end button
Biotech

BeiGene drops TIGIT drug over poor phase 3 lung cancer prospects

BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT antibody.
James Waldron Apr 3, 2025 8:05am
graphic image of different colored hands shaking

BeiGene, Brii and Ideaya ring in 2025 with deals

Jan 2, 2025 8:30am
pay deal hand over cash licensing transaction money

BeiGene inks $150M deal to follow cancer trail blazed by Amgen

Dec 13, 2024 9:11am
Gavel hammer of judge and stethoscope on black background

AbbVie sues BeiGene over blood cancer drug trade secrets

Sep 11, 2024 10:17am
BeiGenes facility in Beijing

BeiGene offers up $1.3B in biobucks for preclinical cancer drug

Nov 21, 2023 7:13am
Deal terminate tear up end deal scrap

Novartis retreats from TIGIT, handing $300M drug back to BeiGene

Jul 11, 2023 9:20am